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Available online xxxxThe standard method of primary neonatal screening for congenital adrenal hyperlasia (CAH), determination of
17-hydroxyprogesterone (17OHP) in heelprick blood, is the object of recurrent controversy because of its poor
diagnostic and economic efficiency. The superior ability of urinary pregnanetriolone levels to discriminate be-
tween infants with andwithout classical CAH has been known for some time, but has not hitherto been exploited
for primary screening. Herewe propose an economical neonatal CAH-screening system based on fluorimetric de-
termination of the product of reaction between urinary pregnanetriolone and phosphoric acid.
© 2016 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Congenital adrenal hyperplasia (CAH) is an inherited metabolic dis-
order caused by autosomal recessive defects in the genes encoding en-
zymes involved in the biosynthesis of mineralocorticoids,
glucocorticoids or sex steroids in the adrenal glands [1]. The most com-
mon such defect, accounting for 90–95% of CAH cases [2], affects
CYP21A2, the gene encoding 21-hydroxylase, which transforms proges-
terone into deoxycorticosterone and 17α-hydroxyprogesterone into
11-deoxycortisol. Unless otherwise stated, “CAH” hereinafter refers to
CAH caused by 21-hydroxylase deficiency (21OHD). The reported fre-
quency of this condition ranges from 1:28,000 in China to 1:280
among Yupik Eskimos, with an average of around 1:14,200 [3].
Depending on the specific mutation suffered, loss of 21-hydroxylase
activity may be complete or only partial, and the degree of 21OHD cor-
relates well, though by nomeans perfectly, with clinical phenotype [4]:
total loss of activity typically results in the most severe form, salt-
wasting CAH; mutations averaging 98% loss in simple virilizing CAH;
and mutations causing 80–90% loss in mild, “non-classical” (late-
onset) CAH. Non-classical CAH, which affects 0.1–0.2% of Caucasians
[5–8], gives rise to no symptoms in early childhood, but later results in
excess androgen levels and accelerated bone aging, and adolescent
and adult females may suffer hirsutism, menstrual irregularity and in-
fertility. In simple virilizing CAH (about a quarter of all “classical” CAH
cases) the effects of excess androgen are already pronounced in early
childhood; newborn girls may have ambiguous external genitalia.
Salt-wasting CAH is a potentially life-threatening condition that, un-
treated, leads within 1–3 weeks of birth to acute adrenal crises, with
poor weight gain, vomiting, diarrhoea, dehydration, failure to thrive,
lethargy, hyponatraemia (due to 21OHD-induced aldosterone deficien-
cy), hyperkalaemia, and shock.This is an open access article under tBecause of its high frequency and life-threatening potential, and be-
cause it can be treated effectively by corticoid replacement therapy, CAH
is in many countries included among the inherited metabolic disorders
screened for at birth. The standard primary screeningmethodmeasures
the 21-hydroxylase substrate 17-hydroxyprogesterone (17OHP) in the
same kind of sample as is generally employed for other neonatal screen-
ing tests, blood obtained by heel prick and transported to the laboratory
in sorbent paper. However, whatever the analytical technique used to
determine 17OHP in these blood samples - the most widespread is
dissociation-enhanced lanthanide fluoroimmunoassay DELFIA®
(PerkinElmer Life Sciences-Wallac Oy, Turku, Finland) – this approach
is bedeviled by the fact that 17OHP levels are generally high in unaffect-
ed newborns, especially if premature, sick or stressed [9–13]. In healthy
newborns 17OHP levels rapidly fall, but their descent is often not com-
pleted before heelprick for neonatal screening (nowadays usually per-
formed no later than the third day of life), which results in widely
disperse values [23]. Additionally, immunoassays suffer from a degree
of cross-reactivity with sulphated steroids produced by the foetal and
neonatal adrenal gland [9–14]. As a result of these two influences,
there is considerable overlap between the 17OHP levels in heelprick
samples of newborns with and without CAH: if a 17OHP screening
threshold of adequate sensitivity is set, around 1% of all newborns test
positive, and about 99% of these positive results will be false [9], making
screening for CAH one of the least cost-effective of neonatal screening
procedures [15–17].
For premature newborns the discrimination problem can be alleviat-
ed to some extent by using different 17OHP thresholds for different ges-
tational age groups [2,18–20]. More generally, it has been reported that
satisfactory sensitivity and positive predictive value can be achieved by
subjecting positive-testing samples to a second-tier test in which liquid
chromatography followed by tandem mass spectrometry (LC-MS/MS)he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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dione, cortisol, 11-deoxycortisol, 21-deoxycortisol), and steroid ratios
are used as the test criterion [9,11,21]. However, LC-MS/MS is an expen-
sive procedure with low throughput (as is genotyping, another second-
tier option [22]), and its application is costly, given the large number of
first-tier false positives.
The basis for a radical possible solution to these problems was laid
more than a decade ago when it was found that urinary
pregnanetriolone differentiated perfectly between newborns with and
without 21OHD [24–26]. The study of Homma et al. [24], was small on
the non-21-OHD side (83 non-21OHD newborns with elevated blood
17OHP versus 50 term and 9 pre-term newborns with classical
21OHD), and the analytical method, gas chromatography with mass
spectrometry, was not suitable for primary screening; but its findings
have since been confirmed in a larger study [13], and there appears to
be no reason why the inexpensive fluorimetric analytical procedure by
means of which pregnane¬triolone was first identified in patients'
urine [27–32] cannot be readily adapted for reliable use in a screening
programme. The major obstacle to the adoption of urinary
pregnanetriolone as the analyte of choice for classical 21OHD screening
seems to be the fact that the collection of urine samples – the basis of the
pioneering neonatal screening programmes of Berry [33,34], Woolf
[35–38] and others – has by many screening laboratories never been
practised, andwas discontinued long ago bymost of those that did orig-
inally practise it.
The neonatal screening laboratory of Galicia (NWSpain) is oneof the
few that still collect urine samples from all newborns to screen for
amino acid disorders, sugar disorders, mucopolysaccharidoses and
oligosaccharidosis, and we are currently working to cover lysosomal
storage disorders (glycosphingolipidoses, GM2 gangliosidoses, neutral
glycosphingolipidoses, glycoproteinoses, mucolipidoses, leukodystro-
phies and others), which are far easier to detect reliably using urine
samples than in blood samples, in which the concentrations of marker
substances are several times lower than in urine [38]. In the remainder
of this article we describe the practical details of newborn urine sample
collection, define a fluorimetry-based method of pregnanetriolone de-
termination that we propose to validate, and outline a broader project
for the evaluation of urinary-pregnanetriolone-based 21OHD screening
in which we hope to enjoy the collaboration of other centres. We end
with some final remarks on the future role of urine analysis in newborn
screening.
2. Urine collection
In our screening system, urine samples, like heelprick blood, are
taken on the third day of life [39], using a piece of Whatman 903 or
Munktell TFN sorbent paper included in the screening kit (Fig. 1). BeforeFig. 1. Sorbent paper.heelprick, half the paper is placed over the infant's genitals (which
should be clean,with no cream, talc, oil or other product thatmight con-
taminate the urine) and is held in place by a diaper or napkin. Upon
heelprick, the infant will generally urinate, after which the adsorbent
paper can be removed and set apart to dry in a horizontal position on
a support with which it makes minimal contact (e.g. a “bed of nails”
made of pins stuck in cardboard, as in Fig. 2) [40]. In a maternity ward
where samples are taken in a single session from all the infants born
three days previously, it is of course necessary to write each infant's
identity data on the sorbent paper before use; this should be done
with a pencil so as to avoid contamination of the sample by ink. If
upon heelprick the infant defecates as well as urinating, the sample
should be discarded (even though the filter paper shows no visible fae-
ces stain, it may bear fecal components eluted by the urine); in these
cases, the other half of the filter paper is held in place with a diaper or
napkin until the infant has urinated again. If the procedure takes place
before discharge, the sample enters the laboratory on the day of collec-
tion; otherwise, if brought by hand or sent by mail.
3. Determination of pregnanetriolone
Sixteen discs 3 mm in diameter, or four 6 mm in diameter, are
punched from the urine-bearing sorbent papers upon their arrival at
our laboratory, and are stirred in the wells of 96-well microtitration
plates containing 300 μL of water each (2 h, or 10 min if a 96-probe ul-
trasound device is used). The eluates thus prepared are currently
employed to screen for the disorders mentioned in the Introduction
by means of a battery of analyses that includes determination of creati-
nine for normalization [41,42]. Though subject to eventual optimization,
the subsequent steps of the pregnanetriolone determination procedure
that we propose to validate, adapted fromRefs. 45 and 46 (see also Refs.
43 and 44), are as follows.
- Transfer 20 μL of eluate to a well of a black quartz microtitration
plate (quartz to withstand heating, black to prevent interference be-
tween cells during fluorimetry – see below).Fig. 2. Bed of nails.
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thick sheet of red silicone below and a 5-mm-thick glass plate above,
secure the sandwichwith bulldog clips, and heat in an oven at 100 °C
for 10 min so as to hydrolyse the sample and destroy steroids that
would otherwise interfere with the determination of
pregnanetriolone [45,46].
- Evaporate to dryness under a stream of nitrogen.
- Add 20 μL of 85% phosphoric acid, sandwich the plate between sili-
cone and glass as before, stir, heat for 5 min at 100 °C, and cool rap-
idly to room temperature.
- Read fluorescence at 530 nm under excitation at 440 nm [27], and
obtain pregnanetriolone concentration from a calibration curve pre-
viously constructed using pure pregnanetriolone.
The excitation and emissionwavelengths, 440 and 530 nm,will like-
ly have to be modified somewhat, these wavelengths having been de-
termined in the original studies [27] with fluorometers in which
wavelength was controlled only coarsely, using optical filters instead
of the finer control methods employed in today's apparatus.
4. Evaluation of urinary-pregnanetriolone-based 21OHD screening
Evaluation of urinary pregnanetriolone as a basis for 21OHD screen-
ing will first require optimization and validation of the fluorimetric an-
alytical method described above, with determination of its limits of
detection and quantification, precision, accuracy, sensitivity, linearity,
and vulnerability to interference. Although the hot acid treatment of
the urine eluate will probably not eliminate all interference from
other steroids, any remaining will doubtless derive, like
pregnanetriolone, from elevated excretion due to CAH, and will accord-
ingly not invalidate the test for screening purposes. Indeed, further ad-
justment of the excitation and emission wavelengths (in addition to
the modifications mentioned in the previous paragraph) may allow
such interferences to be exploited to good effect.
Once the analytical method has been optimized and validated, it will
be necessary to evaluate its use for screening, determining diagnostic
sensitivity and specificity, positive and negative predictive values, posi-
tive and negative likelihood ratios, diagnostic efficiency, and ROC curve
[47]. Initially, the diagnostic threshold value specified by Homma et al.
[24], 0.1 mg/(g creatinine), may be used, though as cases accumulate
it may be found appropriate to establish a higher cutoff, given the prob-
able contribution of fluorophores other than pregnanetriolone. New-
borns testing positive would be followed up by quantification of
serum 17OHP in serial blood samples (3:100 (v/v) propanol/heptane
may be used to eliminate interfering steroids [48]), by measurement
of 21-hydroxylase activity, and by any other tests deemed necessary,
such as genotyping. No follow up of newborns with negative urinary
pregnanetriolone tests would be necessary if, as in the authors' health
system, the existence of undetected cases (false negatives) could readily
be ascertained through on-line access to hospital records.
5. The role of urine samples in newborn screening
5.1. Concluding remarks
There is every reason to believe that the approach to CAH screening
proposed here will prove to have better diagnostic characteristics - in
particular superior positive predictive value and sensitivity - than the
standard 17OHP-based approach, which is the object of recurrent con-
troversy (quite recently in regard to its sensitivity [20] and its utility
for pre-term infants [20]). The systemproposed herewould undoubted-
ly bemore cost efficient than 17OHP-based screening, simply because it
requires considerably less expensive consumables. If our expectations
regarding its diagnostic efficiency are fulfilled, the major foreseeableimpediment to its widespread introduction would be unwillingness to
collect urine samples as well as blood samples.
Urine samples, employed by the earliest phenylketonuria screening
programmes [33–38,49], largely fell into disuse when the Guthrie test
became the method of choice for phenylketonuria screening. We have
argued elsewhere that their continued use is beneficial and advanta-
geous in screening for a number of congenital disorders [38], and we
have argued here that the possibility of including 21OHD in this group
should be taken seriously and investigated. It is alsowell-known that ly-
sosomal storage disorders are far easier to detect reliably using urine
samples than blood samples, in which the concentrations of marker
substances are several times lower than in urine [50]. In all these
cases, urine analysis can or seems likely to provide a screening proce-
dure – or at least a first-tier procedure – that is less expensive and no
less diagnostically efficient than blood spot analysis. Is it not time that
urine sampling be restored to the neonatal screening armamentarium?
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